Latest news with #TopiramateHCl
Business Standard
06-05-2025
- Business
- Business Standard
Senores Pharmaceuticals gains on acquiring Topiramate tablets from Wockhardt
Senores Pharmaceuticals added 1.53% to Rs 513.15 after it has signed an agreement with with Wockhardt to acquired USFDA-approved Topiramate HCl 25, 50, 100 and 200 mg tablets, used to treat epilepsy and migraine. Shares of Wockhardt declined 2.15% to Rs 1,267 on the BSE. The market size of Topiramate tablet in the USA was USD 111.47 million (MAT December 2024) as per IQVIA. The acquisition will be funded through the initial public offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus. Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. Wockhardt is a research based global pharmaceutical and Biotech Company.
Time of India
06-05-2025
- Business
- Time of India
Senores Pharma shares in focus after deal to acquire USFDA-approved epilepsy drug from Wockhardt
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Senores Pharmaceuticals are likely to be in focus on Tuesday after the company announced it is acquiring the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate tablets from Wockhardt , expanding its U.S. product Pharmaceuticals Ltd (SPL), through its wholly owned subsidiary Senores Pharmaceuticals, Inc, USA (SPI), has signed an agreement to acquire the ANDA for Topiramate HCl 25, 50, 100, and 200 mg tablets. Topiramate is used in the treatment of epilepsy and migraine, with the US market valued at about USD 111.47 million as of December 2024, according to company said in a statement that the acquisition will be funded through proceeds from its December IPO, in line with the objectives outlined in its Red Herring made a strong stock market debut in December 2024, listing at a 53.45% premium at Rs 600 on the NSE and at Rs 593.7 on the BSE, a 51.8% jump over its upper price band of Rs then, however, shares have retreated, dropping 8% over the past three months, 5% in the last month, and 2% over the past stock is currently trading below all five key simple moving averages — the 5-day, 10-day, 20-day, 30-day, and 50-day SMAs. The 14-day Relative Strength Index (RSI) stands at 37.2, signaling the stock is approaching oversold levels but has yet to cross the typical 30 threshold.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Business Standard
05-05-2025
- Business
- Business Standard
Senores inks deal to acquire Wockhardt's ANDA for Topiramate
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreement today to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Topiramate HCl 25, 50, 100 and 200 mg tablets (Topiramate) from Wockhardt. Topiramate is indicated as a treatment of epilepsy and migraine. The market size of Topiramate Tablet in the USA was ~USD 111.47 Mn (MAT December 2024)1 as per IQVIA. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
